These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38706776)

  • 1.
    Krencz I; Sztankovics D; Sebestyén A; Pápay J; Dankó T; Moldvai D; Lutz E; Khoor A
    Pathol Oncol Res; 2024; 30():1611593. PubMed ID: 38706776
    [No Abstract]   [Full Text] [Related]  

  • 2. Correlation between immunohistochemistry and RICTOR fluorescence in situ hybridization amplification in small cell lung carcinoma.
    Krencz I; Sebestyen A; Papay J; Lou Y; Lutz GF; Majewicz TL; Khoor A
    Hum Pathol; 2019 Nov; 93():74-80. PubMed ID: 31454632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 amplification is associated with an immune cell rich phenotype in squamous cell cancer of the lung.
    Goldmann T; Marwitz S; Nitschkowski D; Krupar R; Backman M; Elfving H; Thurfjell V; Lindberg A; Brunnström H; La Fleur L; Mezheyeuski A; Mattsson JSM; Botling J; Micke P; Strell C
    Cancer Immunol Immunother; 2021 Sep; 70(9):2577-2587. PubMed ID: 33576873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples.
    Casadevall D; Clavé S; Taus Á; Hardy-Werbin M; Rocha P; Lorenzo M; Menéndez S; Salido M; Albanell J; Pijuan L; Arriola E
    Clin Lung Cancer; 2017 Nov; 18(6):682-691.e5. PubMed ID: 28549836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity.
    Straub M; Drecoll E; Pfarr N; Weichert W; Langer R; Hapfelmeier A; Götz C; Wolff KD; Kolk A; Specht K
    Oncotarget; 2016 Mar; 7(11):12024-34. PubMed ID: 26918453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between RICTOR overexpression and amplification in advanced solid tumors.
    Bang H; Ahn S; Ji Kim E; Kim ST; Park HY; Lee J; Kim KM
    Pathol Res Pract; 2020 Jan; 216(1):152734. PubMed ID: 31740232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma.
    Takada K; Okamoto T; Toyokawa G; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y
    Lung Cancer; 2017 Feb; 104():7-15. PubMed ID: 28213003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of phosphatase and tensin homolog and programmed cell death ligand 1 in adenosquamous carcinoma of the lung.
    Hlaing AM; Furusato B; Udo E; Kitamura Y; Souda M; Masutani M; Fukuoka J
    Biochem Biophys Res Commun; 2018 Sep; 503(4):2764-2769. PubMed ID: 30100056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer.
    Yoshimura K; Inoue Y; Tsuchiya K; Karayama M; Yamada H; Iwashita Y; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
    Lung Cancer; 2020 Mar; 141():21-31. PubMed ID: 31931443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC).
    Jiang L; Su X; Zhang T; Yin X; Zhang M; Fu H; Han H; Sun Y; Dong L; Qian J; Xu Y; Fu X; Gavine PR; Zhou Y; Tian K; Huang J; Shen D; Jiang H; Yao Y; Han B; Gu Y
    Oncotarget; 2017 Apr; 8(16):26845-26857. PubMed ID: 28460468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of Responsiveness to PD-L1/PD-1 Inhibitors Using miRNA Profiles Associated With PD-L1 Expression in Lung Adenocarcinoma and Squamous Cell Carcinoma.
    Koh YW; Han JH; Haam S; Lee HW
    Anticancer Res; 2024 May; 44(5):2081-2089. PubMed ID: 38677736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer.
    Inoue Y; Yoshimura K; Mori K; Kurabe N; Kahyo T; Mori H; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
    Oncotarget; 2016 May; 7(22):32113-28. PubMed ID: 27050074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-expression of IDO1 and PD-L1 in lung squamous cell carcinoma: Potential targets of novel combination therapy.
    Takada K; Kohashi K; Shimokawa M; Haro A; Osoegawa A; Tagawa T; Seto T; Oda Y; Maehara Y
    Lung Cancer; 2019 Feb; 128():26-32. PubMed ID: 30642449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered expression of programmed death-ligand 1 after neo-adjuvant chemotherapy in patients with lung squamous cell carcinoma.
    Song Z; Yu X; Zhang Y
    Lung Cancer; 2016 Sep; 99():166-71. PubMed ID: 27565935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Clinicopathological and Prognostic Analysis of PD-L2 Expression in Surgically Resected Primary Lung Squamous Cell Carcinoma.
    Matsubara T; Takada K; Azuma K; Takamori S; Toyokawa G; Haro A; Osoegawa A; Tagawa T; Kawahara A; Akiba J; Okamoto I; Nakanishi Y; Oda Y; Hoshino T; Maehara Y
    Ann Surg Oncol; 2019 Jun; 26(6):1925-1933. PubMed ID: 30815803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Morphometric analysis of nuclear shape irregularity as a novel predictor of programmed death-ligand 1 expression in lung squamous cell carcinoma.
    Saito-Koyama R; Tamai K; Yasuda J; Okamura Y; Yamazaki Y; Inoue C; Miki Y; Abe J; Oishi H; Sato I; Sasano H
    Virchows Arch; 2024 Apr; 484(4):609-620. PubMed ID: 37171482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the programmed death-ligand 1 mRNA expression and immunopositivity and their correlation with survival outcomes in Indian lung cancer patients.
    Kumar S; Pandey M; Mir IA; Mukhopadhyay A; Sharawat SK; Jain D; Saikia J; Malik PS; Kumar S; Mohan A
    Hum Cell; 2022 Jan; 35(1):286-298. PubMed ID: 34786661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non-Small Cell Lung Cancer.
    Ikeda S; Okamoto T; Okano S; Umemoto Y; Tagawa T; Morodomi Y; Kohno M; Shimamatsu S; Kitahara H; Suzuki Y; Fujishita T; Maehara Y
    J Thorac Oncol; 2016 Jan; 11(1):62-71. PubMed ID: 26762740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition.
    Kim ST; Kim SY; Klempner SJ; Yoon J; Kim N; Ahn S; Bang H; Kim KM; Park W; Park SH; Park JO; Park YS; Lim HY; Lee SH; Park K; Kang WK; Lee J
    Ann Oncol; 2017 Mar; 28(3):547-554. PubMed ID: 28028034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An RNA-RNA crosstalk network involving HMGB1 and RICTOR facilitates hepatocellular carcinoma tumorigenesis by promoting glutamine metabolism and impedes immunotherapy by PD-L1+ exosomes activity.
    Wei Y; Tang X; Ren Y; Yang Y; Song F; Fu J; Liu S; Yu M; Chen J; Wang S; Zhang K; Tan Y; Han Z; Wei L; Zhang B; Cheng Z; Li L; Wang H
    Signal Transduct Target Ther; 2021 Dec; 6(1):421. PubMed ID: 34916485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.